PURPOSE: To empirically determine clinically meaningful cut-scores on the 0-10 response scale of the revised Piper Fatigue Scale (PFS-R) and its shorter version (PFS-12). Breast cancer survivors were classified (i.e., none, mild, moderate, or severe fatigue) based on the cut-scores, and relationships between these cut-scores and decrements in health-related quality of life (HRQOL) were examined. METHODS: A total of 857 breast cancer survivors, stages in situ-IIIa, from the Health, Eating, Activity, and Lifestyle (HEAL) Study were eligible. Survivors completed the PFS-R, SF-36, and a sexual health scale approximately 3 years after diagnosis. Multivariate analysis of covariance was used to examine five fatigue severity cut-score models, controlling for demographics, clinical characteristics, comorbidity, and antidepressant use. Multivariate regression was used to examine HRQOL decrements by cut-score category. RESULTS: Analyses supported two similar fatigue severity cut-score models for the PFS-R and PFS-12: Model A.) none (0), mild (1-3), moderate (4-6), and severe (7-10); and Model D.) none (0), mild (1-2), moderate (3-5), and severe (6-10). For every threshold increase in fatigue severity, clinically meaningful decrements in physical, mental, and sexual health scores were observed, supporting construct validity of the fatigue cut-scores. CONCLUSION: Standardized fatigue cut-scores may enhance interpretability and comparability across studies and populations and guide treating planning.
PURPOSE: To empirically determine clinically meaningful cut-scores on the 0-10 response scale of the revised Piper Fatigue Scale (PFS-R) and its shorter version (PFS-12). Breast cancer survivors were classified (i.e., none, mild, moderate, or severe fatigue) based on the cut-scores, and relationships between these cut-scores and decrements in health-related quality of life (HRQOL) were examined. METHODS: A total of 857 breast cancer survivors, stages in situ-IIIa, from the Health, Eating, Activity, and Lifestyle (HEAL) Study were eligible. Survivors completed the PFS-R, SF-36, and a sexual health scale approximately 3 years after diagnosis. Multivariate analysis of covariance was used to examine five fatigue severity cut-score models, controlling for demographics, clinical characteristics, comorbidity, and antidepressant use. Multivariate regression was used to examine HRQOL decrements by cut-score category. RESULTS: Analyses supported two similar fatigue severity cut-score models for the PFS-R and PFS-12: Model A.) none (0), mild (1-3), moderate (4-6), and severe (7-10); and Model D.) none (0), mild (1-2), moderate (3-5), and severe (6-10). For every threshold increase in fatigue severity, clinically meaningful decrements in physical, mental, and sexual health scores were observed, supporting construct validity of the fatigue cut-scores. CONCLUSION: Standardized fatigue cut-scores may enhance interpretability and comparability across studies and populations and guide treating planning.
Authors: N J Vogelzang; W Breitbart; D Cella; G A Curt; J E Groopman; S J Horning; L M Itri; D H Johnson; S L Scherr; R K Portenoy Journal: Semin Hematol Date: 1997-07 Impact factor: 3.851
Authors: Anna L Schwartz; Paula M Meek; Lillian M Nail; James Fargo; Margaret Lundquist; Melissa Donofrio; Marilyn Grainger; Terry Throckmorton; Magdalena Mateo Journal: J Clin Epidemiol Date: 2002-03 Impact factor: 6.437
Authors: Shahpar Haghighat; Mohammad Esmail Akbari; Kourosh Holakouei; Abbas Rahimi; Ali Montazeri Journal: Support Care Cancer Date: 2003-05-03 Impact factor: 3.603
Authors: Anne McTiernan; Kumar B Rajan; Shelley S Tworoger; Melinda Irwin; Leslie Bernstein; Richard Baumgartner; Frank Gilliland; Frank Z Stanczyk; Yutaka Yasui; Rachel Ballard-Barbash Journal: J Clin Oncol Date: 2003-05-15 Impact factor: 44.544
Authors: Jordan M Harrison; Matthew A Davis; Debra L Barton; Nancy K Janz; Susan J Pressler; Christopher R Friese Journal: Support Care Cancer Date: 2017-03-08 Impact factor: 3.603
Authors: Hsiao-Lan Wang; Ming Ji; Connie Visovsky; Carmen S Rodriguez; Amanda F Elliott; Clement K Gwede; Tapan A Padhya; Marion B Ridley; Susan C McMillan Journal: J Adv Pract Oncol Date: 2016-01-01
Authors: Francisco Álvarez-Salvago; Ana Lara-Ramos; Irene Cantarero-Villanueva; Maryna Mazheika; Antonio Mundo-López; Noelia Galiano-Castillo; Carolina Fernández-Lao; Manuel Arroyo-Morales; Olga Ocón-Hernández; Francisco Artacho-Cordón Journal: Int J Environ Res Public Health Date: 2020-05-21 Impact factor: 3.390
Authors: Chao-Pin Hsiao; Mei-Kuang Chen; Martina L Veigl; Rodney Ellis; Matthew Cooney; Barbara Daly; Charles Hoppel Journal: Cancer Manag Res Date: 2019-07-18 Impact factor: 3.989